Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberta Faccio

Showing results (71-80 of 78) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 78 results.
Nature Communications|June 9, 2016
Stromal senescence establishes an immunosuppressive microenvironment that drives tumorigenesisMegan K Ruhland, Andrew J Loza, Aude-Helene Capietto, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|September 17, 2013
MHC class II transactivator is an in vivo regulator of osteoclast differentiation and bone homeostasis co-opted from adaptive immunityElisa Benasciutti, Elisabetta Mariani, Laura Oliva, et al.
Nature Communications|June 11, 2026
Bone-derived Osterix+ osteolineage cells are a source of tumor-promoting myofibroblastic cancer-associated fibroblasts in breast cancerGiulia Furesi, Carisa Zeng, Emily M Eul, et al.
Nature Communications|March 30, 2018
Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillanceMelissa A Meyer, John M Baer, Brett L Knolhoff, et al.
Cell Reports|January 4, 2016
Stromal-Initiated Changes in the Bone Promote Metastatic Niche DevelopmentXianmin Luo, Yujie Fu, Andrew J Loza, et al.
Cell|August 14, 2020
TREM2 Modulation Remodels the Tumor Myeloid Landscape Enhancing Anti-PD-1 ImmunotherapyMartina Molgora, Ekaterina Esaulova, William Vermi, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 17, 2009
Oxytocin is an anabolic bone hormoneRoberto Tamma, Graziana Colaianni, Ling-ling Zhu, et al.
Cancer Research|May 25, 2016
Antagonizing Integrin β3 Increases Immunosuppression in CancerXinming Su, Alison K Esser, Sarah R Amend, et al.
Pageof 8

Showing results (71-80 of 78) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 78 results.
Nature Communications|June 9, 2016
Stromal senescence establishes an immunosuppressive microenvironment that drives tumorigenesisMegan K Ruhland, Andrew J Loza, Aude-Helene Capietto, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|September 17, 2013
MHC class II transactivator is an in vivo regulator of osteoclast differentiation and bone homeostasis co-opted from adaptive immunityElisa Benasciutti, Elisabetta Mariani, Laura Oliva, et al.
Nature Communications|June 11, 2026
Bone-derived Osterix+ osteolineage cells are a source of tumor-promoting myofibroblastic cancer-associated fibroblasts in breast cancerGiulia Furesi, Carisa Zeng, Emily M Eul, et al.
Nature Communications|March 30, 2018
Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillanceMelissa A Meyer, John M Baer, Brett L Knolhoff, et al.
Cell Reports|January 4, 2016
Stromal-Initiated Changes in the Bone Promote Metastatic Niche DevelopmentXianmin Luo, Yujie Fu, Andrew J Loza, et al.
Cell|August 14, 2020
TREM2 Modulation Remodels the Tumor Myeloid Landscape Enhancing Anti-PD-1 ImmunotherapyMartina Molgora, Ekaterina Esaulova, William Vermi, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 17, 2009
Oxytocin is an anabolic bone hormoneRoberto Tamma, Graziana Colaianni, Ling-ling Zhu, et al.
Cancer Research|May 25, 2016
Antagonizing Integrin β3 Increases Immunosuppression in CancerXinming Su, Alison K Esser, Sarah R Amend, et al.
Pageof 8